APA (7th ed.) Citation

Voss, M. H., Hierro, C., Heist, R. S., Cleary, J. M., Meric-Bernstam, F., Tabernero, J., . . . Baselga, J. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical cancer research, 25(9), 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959

Chicago Style (17th ed.) Citation

Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research 25, no. 9 (2019): 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959.

MLA (9th ed.) Citation

Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research, vol. 25, no. 9, 2019, p. 2699, https://doi.org/10.1158/1078-0432.CCR-18-1959.